Stephen V Liu/X
Apr 11, 2025, 05:53
Stephen V Liu: Early SRS to brain metastases at diagnosis in patients with EGFR or ALK NSCLC when using CNS penetrant TKIs
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared an article by Luke R. G. Pike, et al. on X:
“Should we adopt early SRS to brain metastases at diagnosis in pts with EGFR or ALK NSCLC when using CNS penetrant TKIs?
Viewpoint in JAMA Oncology notes lack of prospective data but SRS improves local control and time to CNS progression.
One concern I have is radiation necrosis – a late toxicity seen more as survival improves.
Uncommon (~10% in some series) but can be very challenging to manage, at times requiring prolonged steroids, off-label bevacizumab, even surgery.
But SRS deferral not always appropriate…”
Management of EGFR-Variant and ALK-Positive Non–Small Cell Lung Cancer Brain Metastasis.
Authors: Luke R. G. Pike, Helena Yu, Chad G. Rusthoven, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 14, 2025, 09:32
Apr 14, 2025, 09:30
Apr 14, 2025, 09:15